CFI-400945 not checked

Treadwell Therapeutics, Inc · 945 · 400945

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.”In the company’s words, NCT04730258 on ClinicalTrials.gov
Tested for
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
Main trialPhase 1/2
“The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.”In the company’s words, NCT04730258 on ClinicalTrials.gov
Other names
945 · 400945

Other drugs for Acute Myeloid Leukemia

All 140 drugs for Acute Myeloid Leukemia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting Jan 2026 A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CFI-400945

Following is part of Solo: you see every change to CFI-400945 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in